Navigation Links
Enigma Diagnostics Announces the Opening of a United States Office

PORTON DOWN, England and SAN FRANCISCO, Dec. 2 /PRNewswire/ --Enigma Diagnostics, the decentralized and point-of-care molecular diagnostics company, announced today the opening of a new U.S. office in San Francisco and the appointment of Chris Melancon as Vice President, Business Development.

The San Francisco office opened on December 1 and is Enigma's first overseas facility established to commercialize Enigma's range of rapid diagnostic instrument systems. Enigma's first product, the Enigma Field Laboratory (FL), was launched in November, and is a fully automated, real-time PCR (polymerase chain reaction) detection system designed for in-field testing by veterinarians, first responders and military personnel.

Chris Melancon will lead the new office and joins Enigma with more than 16 years experience in life sciences and information technology industries, including senior positions at Applied Biosystems and Siebel Systems, a division of Oracle Corporation. His work in emerging markets included biological and influenza surveillance and pathogen detection.

During his three-year tenure at ABI, Chris managed the large scale PCR reagents business for anthrax testing at U.S. Postal Service facilities and commercialized additional pathogen detection kits for European Union customers. He is a graduate of the U.S. Military Academy at West Point and Tulane University's Freeman School of Business.

"The opening of the San Francisco office and Chris' appointment underpins our commitment to a U.S. commercialization strategy as we expand our operations internationally. We are very pleased to have Chris with his proven track record join Enigma at this important stage of our growth," stated John McKinley, Chairman of Enigma Diagnostics.


    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    +44 1980 590131

    U.S. Contacts:
    Richard Lewis Communications, Inc.
    Megan Dubrowski - Media
    Cecelia Heer - Investors

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion dollar markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialization strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including U.S., EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit

SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
3. Enigma Signs Real-Time PCR Licences With Applera
4. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
5. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
6. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
7. Strategic Diagnostics Updates Roth Conference Presentation Time
8. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
9. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
10. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
11. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list ... facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up ...
Breaking Biology Technology:
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
Breaking Biology News(10 mins):